Hoth Therapeutics (NASDAQ:HOTH)provides an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19.

Hoth Therapeutics (NASDAQ: Hoth)提供了HT-002用于预防和/或治疗Sars-CoV-2或COVID-19的临床前研究的最新进展。

There are three leading peptide candidates that have been optimized chemically to maximize the potential viral inhibition.

有三种领先的候选肽经过化学优化以最大化潜在的病毒抑制。

One of the peptide candidates has demonstrated low level viral inhibition assay with no toxicity to the host cell. One or more of the optimized peptide candidates may be combined to achieve maximum viral inhibition.

其中一种候选肽被证明是低水平的病毒抑制试验，对宿主细胞没有毒性。可将一种或多种优化的候选肽组合在一起以达到最大的病毒抑制效果。

Peptide sequence modeling analysis supports that these optimized peptides could be effective against the emerging U.K. and South African SARS-CoV-2 strain variants.

肽序列建模分析表明，这些优化肽对英国和南非新出现的SARS-CoV-2菌株有效。

The research is being led by inventor Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at Virginia Commonwealth University, College of Engineering.

这项研究由发明家迈克尔·h·彼得斯博士领导，他是弗吉尼亚联邦大学工程学院化学和生命科学工程系的教授。

HOTH shares are up 2.7% premarket trading at $2.68.

霍斯股价在盘前交易中上涨2.7%，至2.68美元。